Results 71 to 80 of about 766 (168)
High ORRs Seen with Tagraxofusp-erzs in BPDCN [PDF]
Cancer Discovery, 2019 Abstract Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant.
openaire +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler +4 more
wiley +1 more source
Tissue‐Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts
American Journal of Hematology, Volume 100, Issue 12, Page 2305-2319, December 2025.ABSTRACT Although all myeloid cells are considered to derive from hematopoietic stem cells, the cells in each myeloid lineage are heterogeneous populations, and their distribution and functions vary, depending on underlying physiologic and pathologic processes, age, sex, and genetic and epigenetic signatures.
Peter Valent +27 more
wiley +1 more source
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, Volume 19, Issue 11, Page 3376-3386, November 2025.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Advanced Science, Volume 12, Issue 30, August 14, 2025.This review summarizes recent advances in understanding the immune microenvironment's role in fibrosis, focusing on phenotypic/functional alterations of immune cells and their dynamic interactions with other cellular constituents within tissues. The authors further explore therapeutic opportunities and challenges in targeting immune microenvironment ...
Xiangqi Chen +6 more
wiley +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights
, 2019 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare clonal hematologic malignancy of plasmacytoid dendritic cell precursors. The presentation and clinical course of BPDCN is widely heterogeneous and was most recently categorized as a distinct ...
Venugopal, Sangeetha +4 more
core +1 more source
Venetoclax in the Therapeutic Strategy for BPDCN Management
eJHaem, Volume 6, Issue 4, August 2025.ABSTRACT Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials. However, several case reports have reported relapses after prolonged treatment, and development of resistance.
Margaux Poussard +15 more
wiley +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy with mixed cellular states encompassing dendritic, myeloid, and lymphoid features.
Jingjing Liu +10 more
core +1 more source
Clinical management of CMML—State of the art
British Journal of Haematology, Volume 207, Issue 2, Page 350-364, August 2025.Patients with chronic myelomonocytic leukaemia (CMML) typically present with clinical feature including splenomegaly, constitutional symptoms and autoimmune phenomena, as well as with pathological blood counts and biological features in the marrow. These characteristics may influence the assignment to prognostic categories such as the CPSSmol and also ...
K. Nachtkamp +3 more
wiley +1 more source
, 2019 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy with poor outcomes. Existing data on the clinical behavior of BPDCN are limited because reported outcomes are from small retrospective series, and standardized ...
Stevenson, Kristen E +16 more
core +1 more source